FDA clears remibrutinib for symptomatic dermographism, a second hives use

The Food and Drug Administration has approved remibrutinib for symptomatic dermographism, adding a second skin condition to the oral drug's label a little over a year after its first [s1]. Sold as RHAPSIDO by Novartis, it is now indicated for adults who stay symptomatic despite an H1 antihistamine, for either chronic spontaneous urticaria — its original 2025 use — or symptomatic dermographism, the change recorded on the label in October 2026 [s1]. The approval record for the supplement is dated 6 October 2026 [s2].

What the condition is

Symptomatic dermographism is a form of chronic inducible urticaria: the skin raises itchy welts along lines where it has been stroked, scratched or pressed. It is diagnosed and graded with a provocation test — the FricTest 4.0, a small device that applies defined pressure and yields a Total Fric Score from 0 to 4 [s1]. Antihistamines are the standard first treatment, but some people stay symptomatic on them, and until now no drug carried a specific label for the condition.

Remibrutinib is a kinase inhibitor — more precisely a BTK inhibitor, blocking Bruton tyrosine kinase, an enzyme that helps drive the mast-cell signalling behind hives. It is taken as a 25 mg tablet twice daily, with or without food [s1].

The trial

The new use rests on RemIND, a randomised, double-blind, placebo-controlled trial [s1]. Participants were adults with symptomatic dermographism for at least four months that remained inadequately controlled on H1 antihistamines, defined by a Total Fric Score of at least 3 and an itch rating of at least 5 on a 0-to-10 scale ten minutes after the provocation test [s1]. They were randomised one-to-one to remibrutinib 25 mg or placebo twice daily for a 24-week controlled period, followed by a 28-week open-label phase in which everyone took the drug; efficacy is based on the 115 patients treated during the controlled period [s1].

The primary endpoint was the share of patients with a complete response — a Total Fric Score of 0 on the provocation test — at week 12 [s1]. Among those on remibrutinib, 17 of 58 (29.3%) cleared the test, against 8 of 57 (14.0%) on placebo — a treatment difference of 15.0 percentage points, with a 95% confidence interval of 0.3 to 29.7 [s1]. That interval stays above zero, but only just at its lower edge: the drug separated from placebo, and the effect could plausibly be as small as a fraction of a percentage point or as large as about 30.

It is worth keeping the denominator in view. This is a complete-clearance measure in roughly 115 patients, and most people on the drug did not reach a Total Fric Score of 0 at week 12. The result establishes a benefit over placebo; it does not mean the welts vanish for everyone.

What to watch

Remibrutinib's label warns of bleeding: mucocutaneous bleeding occurred in 9% of patients across the clinical trials, treatment should be interrupted if bleeding appears, and it should be paused three to seven days before and after surgery [s1]. Antithrombotic drugs taken alongside it may add to the risk [s1]. The label also says to avoid live or live-attenuated vaccines during treatment, and to avoid use in hepatic impairment [s1]. The most common adverse reactions, each above 3%, were nasopharyngitis, bleeding, headache, nausea and abdominal pain [s1].

The indication is specific: adults whose symptomatic dermographism, or chronic spontaneous urticaria, is still active on an antihistamine [s1]. It is not a first-line treatment, and the label does not extend to other inducible urticarias. For a condition that has never had a drug of its own, a labelled option matters; the honest frame is that it clearly beats placebo on a strict clearance test, in a modest-sized trial, over three months.

This article is informational and does not constitute medical advice. Decisions about treating chronic hives belong with a patient and their clinician.